Clinical and Economic Evaluation of Anticoagulant Interventions for Stroke Prevention in Patients with Atrial Fibrillation

Many new anticoagulant interventions have emerged for stroke prevention in atrial fibrillation such as novel oral anticoagulants (NOACs) and warfarin care bundles. To date, the overall efficacy and cost-effectiveness of warfarin care bundles in comparison with NOACs is still unknown, especially in the healthcare context of low- and middle-income countries. Therefore, this thesis aimed to explore the clinical and economic outcomes of these interventions in patients with atrial fibrillation, in such healthcare setting. This thesis demonstrated the value of clinical evidence obtained systematically and how economic evaluation may facilitate healthcare decision-making on the choices of anticoagulants, based on scarce resources allocation.